Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial

PLoS ONE

Volumn 13, Issue 1, 2018, Pages

  Trigo, Jose M ^a   Soliman, Alexandra ^a   Quilty, Lena C ^a,b   Fischer, Benedikt ^a,b,c,d   Rehm, Jürgen ^a,b,c,e   Selby, Peter ^a,b,c   Barnes, Allan J ^f,h   Huestis, Marilyn A ^f,i   George, Tony P ^a,b   Streiner, David L ^b,g   Staios, Gregory ^a   Le Foll, Bernard ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

ⁱ UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NABIXIMOLS; PLACEBO; CANNABIDIOL; DRONABINOL;

ABSTINENCE; ADULT; ARTICLE; CANNABIS ADDICTION; CANNABIS USE; CLINICAL ARTICLE; COGNITIVE BEHAVIORAL THERAPY; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CRAVING; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; MOTIVATIONAL INTERVIEWING; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; COGNITIVE THERAPY; CRAVING; DRUG COMBINATION; MIDDLE AGED; MOTIVATION; WITHDRAWAL SYNDROME; YOUNG ADULT;

ADULT; CANNABIDIOL; COGNITIVE THERAPY; CRAVING; DOUBLE-BLIND METHOD; DRONABINOL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; MOTIVATION; PILOT PROJECTS; PLACEBOS; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 85041209290     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0190768     Document Type: Article

References (66)

1. UNODC (2016) United Nations Office on Drugs and Crime. World Drug Report 2016. New York: United Nations.
2. UNODC (2015) United Nations Office on Drugs and Crime. World Drug Report 2015. In: Nations U, editor. New York
3. Fischer B, Imtiaz S, Rudzinski K, Rehm J (2016) Crude estimates of cannabis-attributable mortality and morbidity in Canada-implications for public health focused intervention priorities. J Public Health (Oxf) 38: 183–188.
4. Fischer B, Rehm J, Hall W (2009) Cannabis use in Canada: the need for a’public health’ approach. Can J Public Health 100: 101–103. PMID: 19839283
5. Room R, Fischer B, Hall W, Lenton S, Reuter P, editors (2010) Cannabis policy: Moving beyond stalemate. New York, NY: Oxford University Press.
6. Crean RD, Tapert SF, Minassian A, Macdonald K, Crane NA, et al. (2011) Effects of chronic, heavy cannabis use on executive functions. J Addict Med 5: 9–15. https://doi.org/10.1097/ADM. 0b013e31820cdd57 PMID: 21643485
7. Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD (2002) Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 42: 71S–81S. PMID: 12412839
8. Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, et al. (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2: 233–238. https://doi.org/10.1016/S2215-0366(14)00117-5 PMID: 26359901
9. Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, et al. (2015) Cannabis effects on driving lateral control with and without alcohol. Drug Alcohol Depend 154: 25–37. https://doi.org/10.1016/j.drugalcdep.2015.06.015 PMID: 26144593
10. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, et al. (2015) Prevalence of Marijuana Use Disorders in the United States Between 2001–2002 and 2012–2013. JAMA Psychiatry 72: 1235–1242. https://doi.org/10.1001/jamapsychiatry.2015.1858 PMID: 26502112
11. Winters KC, Lee CY (2008) Likelihood of developing an alcohol and cannabis use disorder during youth: association with recent use and age. Drug Alcohol Depend 92: 239–247. https://doi.org/10.1016/j.drugalcdep.2007.08.005 PMID: 17888588
12. Lev-Ran S, Le Strat Y, Imtiaz S, Rehm J, Le Foll B (2013) Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample. Am J Addict 22: 7–13. https://doi.org/10.1111/j.1521-0391.2013.00321.x PMID: 23398220
13. Wagner FA, Anthony JC (2002) From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 26: 479–488. https://doi.org/10.1016/S0893-133X(01)00367-0 PMID: 11927172
14. Marshall K, Gowing L, Ali R, Le Foll B (2014) Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 12: CD008940.
15. WHO (2016) World Health Organization. The health and social effects of nonmedical cannabis use. WHO Library Cataloguing-in-Publication Data.
16. Copeland J, Pokorski I (2016) Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review. Subst Abuse Rehabil 7: 41–53. https://doi.org/10.2147/SAR.S89857 PMID: 27217809
17. Panlilio LV, Justinova Z, Trigo JM, Le Foll B (2016) Screening and Evaluation of Medications for Treating Cannabis Use Disorder. International Review of Neurobiology In production.
18. Vandrey R, Haney M (2009) Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 23: 543–553. https://doi.org/10.2165/00023210-200923070-00001 PMID: 19552483
19. Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, et al. (2017) A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend 177: 249–257. https://doi.org/10.1016/j.drugalcdep.2017.04.020 PMID: 28623823
20. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B (2007) Oral delta-9-tetrahydrocannabi-nol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86: 22–29. https://doi.org/10.1016/j.drugalcdep.2006.04.014 PMID: 16769180
21. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, et al. (2008) Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) 197: 157–168.
22. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, et al. (2004) Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29: 158–170. https://doi.org/10.1038/sj.npp.1300310 PMID: 14560320
23. Hart CL, Haney M, Ward AS, Fischman MW, Foltin RW (2002) Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend 67: 301–309. PMID: 12127201
24. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, et al. (2011) Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 116: 142–150. https://doi.org/10.1016/j.drugalcdep.2010.12.010 PMID: 21310551
25. Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, et al. (2013) The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend 128: 64–70. https://doi.org/10.1016/j.drugalcdep.2012.08.001 PMID: 22921474
26. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, et al. (2013) Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 38: 1557–1565. https://doi.org/10.1038/npp.2013.54 PMID: 23443718
27. Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, et al. (2016) Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology (Berl) 233: 2469–2478.
28. Prud’homme M, Cata R, Jutras-Aswad D (2015) Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. Subst Abuse 9: 33–38.
29. Allsop DJ, Lintzeris N, Copeland J, Dunlop A, McGregor IS (2015) Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal. Clin Pharmacol Ther 97: 571–574. https://doi.org/10.1002/cpt.109 PMID: 25777582
30. Trigo JM, Lagzdins D, Rehm J, Selby P, Gamaleddin I, et al. (2016) Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend 161: 298–306. https://doi.org/10.1016/j.drugalcdep.2016.02.020 PMID: 26925704
31. Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, et al. (2014) Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry 71: 281–291. https://doi.org/10.1001/jamapsychiatry.2013.3947 PMID: 24430917
32. First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P); Research NYB, editor: New York State Psychiatric Institute.
33. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychological Reports 10: 799–812.
34. Levine J, Schooler NR (1986) SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22: 343–381. PMID: 3774930
35. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32: 50–55. PMID: 13638508
36. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62. PMID: 14399272
37. Sobell LC, Sobell MB, Leo GI, Cancilla A (1988) Reliability of a timeline method: assessing normal drinkers’ reports of recent drinking and a comparative evaluation across several populations. Br J Addict 83: 393–402. PMID: 3395719
38. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991) The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86: 1119–1127. PMID: 1932883
39. McLellan AT, Luborsky L, Woody GE, O’Brien CP (1980) An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 168: 26–33. PMID: 7351540
40. Beck AT, Steer RA (1987) Beck Depression Inventory. Philadelphia, PA, Center for Cognitive Therapy.
41. Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, et al. (2013) The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology (Berl) 227: 177–192.
42. McNair DM, Lorr M, Droppleman LF (1971) Manual for the profile of mood states. San Diego, CA: Educational and Industrial Testing Services.
43. Budney AJ, Novy PL, Hughes JR (1999) Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94: 1311–1322. PMID: 10615717
44. Heishman SJ, Evans RJ, Singleton EG, Levin KH, Copersino ML, et al. (2009) Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend 102: 35–40. https://doi.org/10.1016/j.drugalcdep.2008.12.010 PMID: 19217724
45. Ellis BW, Johns MW, Lancaster R, Raptopoulos P, Angelopoulos N, et al. (1981) The St. Mary’s Hospital sleep questionnaire: a study of reliability. Sleep 4: 93–97. PMID: 7232974
46. Mason BJ, Crean R, Goodell V, Light JM, Quello S, et al. (2012) A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 37: 1689–1698. https://doi.org/10.1038/npp.2012.14 PMID: 22373942
47. Nordstrom BR, Levin FR (2007) Treatment of cannabis use disorders: a review of the literature. Am J Addict 16: 331–342. https://doi.org/10.1080/10550490701525665 PMID: 17882603
48. SAMHSA (2005) Brief COUNSELING for MARIJUANA DEPENDENCE A Manual for Treating Adults.
49. Steinberg KL, Roffman RA, Carroll KM, McRee B, Babor TF, et al. (2005) Brief counseling for marijuana dependence: a manual for treating adults. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration.
50. Blackburn IM, James IA, Milne DL, Reichelt FK, Garland A, et al. (2001) Cognitive therapy scale—revised (CTS-R). Newcastle-upon-Tyne: Newcastle Cognitive and Behavioural Therapies Centre.
51. Martino S, Ball SA, Gallon SL, Hall D, Garcia M, et al. (2006) Motivational interviewing assessment: Supervisory tools for enhancing proficiency. Salem, OR: Northwest Frontier Addiction Technology Transfer Center, Oregon Health and Science University.
52. Lowe RH, Karschner EL, Schwilke EW, Barnes AJ, Huestis MA (2007) Simultaneous quantification of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-Delta9-tetrahydro-cannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocus-ing, and electron impact-mass spectrometry. J Chromatogr A 1163: 318–327. https://doi.org/10.1016/j.chroma.2007.06.069 PMID: 17640656
53. Schwope DM, Scheidweiler KB, Huestis MA (2011) Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 401: 1273–1283. https://doi.org/10.1007/s00216-011-5197-7 PMID: 21727996
54. Trigo JM, Soliman A, Staios G, Quilty L, Fischer B, et al. (2016) Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series. J Addict Med 10: 274–279. https://doi.org/10.1097/ADM.0000000000000229 PMID: 27261670
55. Karschner EL, Darwin WD, McMahon RP, Liu F, Wright S, et al. (2011) Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 89: 400–407. https://doi.org/10.1038/clpt.2010.318 PMID: 21289620
56. Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, et al. (2016) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend In press.
57. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, et al. (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764–774. https://doi.org/10.1038/npp.2009.184 PMID: 19924114
58. Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, et al. (2016) Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. Neuropsychopharmacology 41: 1974–1982. https://doi.org/10.1038/npp.2015.367 PMID: 26708108
59. Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK (2013) Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 38: 2433–2436. https://doi.org/10.1016/j.addbeh.2013.03.011 PMID: 23685330
60. Crippa JA, Hallak JE, Machado-de-Sousa JP, Queiroz RH, Bergamaschi M, et al. (2013) Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther 38: 162–164. https://doi.org/10.1111/jcpt.12018 PMID: 23095052
61. Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, et al. (2006) Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict 15: 8–14. https://doi.org/10.1080/ 10550490500418997 PMID: 16449088
62. Levin KH, Copersino ML, Heishman SJ, Liu F, Kelly DL, et al. (2010) Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend 111: 120–127. https://doi.org/10.1016/j.drugalcdep.2010.04.010 PMID: 20510550
63. Marshall K, Gowing L, Ali R, Le Foll B (2014) Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev: CD008940. https://doi.org/10.1002/14651858.CD008940.pub2 PMID: 25515775
64. Cousijn J, van Benthem P, van der Schee E, Spijkerman R (2015) Motivational and control mechanisms underlying adolescent cannabis use disorders: A prospective study. Dev Cogn Neurosci 16: 36–45. https://doi.org/10.1016/j.dcn.2015.04.001 PMID: 25922296
65. Balter RE, Cooper ZD, Haney M (2014) Novel Pharmacologic Approaches to Treating Cannabis Use Disorder. Curr Addict Rep 1: 137–143. https://doi.org/10.1007/s40429-014-0011-1 PMID: 24955304
66. Allsop DJ, Copeland J, Norberg MM, Fu S, Molnar A, et al. (2012) Quantifying the clinical significance of cannabis withdrawal. PLoS One 7: e44864. https://doi.org/10.1371/journal.pone.0044864 PMID: 23049760